Multi-Institutional Phase II Study of Selumetinib in Patients With Metastatic Biliary Cancers von BEKAII-SAAB, Tanios, PHELPS, Mitch A, VASKO, Vasily V, BLOOMSTON, Mark, MARSH, William, AUSTIN DOYLE, L, ELLISON, Gilian, GREVER, Michael, RINGEL, Matthew D, VILLALONA-CALERO, Miguel A, XIAOBAI LI, SAJI, Motoyasu, GOFF, Laura, WOOK KAUH, John Sae, O'NEIL, Bert H, BALSOM, Stephanie, BALINT, Catherine, LIERSEMANN, Ryan

Volltext

Phase II Study of the Mitogen-Activated Protein Kinase 1/2 Inhibitor Selumetinib in Patients With Advanced Hepatocellular Carcinoma von O'NEIL, Bert H, GOFF, Laura W, SEBTI, Said M, SULLIVAN, Daniel M, WOOK KAUH, John Sae, STROSBERG, Jonathan R, BEKAII-SAAB, Tanios S, LEE, Ruey-Min, KAZI, Aslamuzzaman, MOORE, Dominic T, LEAROYD, Maria, LUSH, Richard M

Volltext

Phase II trial of bortezomib plus doxorubicin in hepatocellular carcinoma (E6202): a trial of the Eastern Cooperative Oncology Group von Ciombor, Kristen K., Feng, Yang, Benson, Al Bowen, Su, Yingjun, Horton, Linda, Short, Sarah P., Kauh, John Sae Wook, Staley, Charles, Mulcahy, Mary, Powell, Mark, Amiri, Katayoun I., Richmond, Ann, Berlin, Jordan

Volltext

LY3022855, an anti–colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody, in patients with advanced solid tumors refractory to standard therapy: phase 1 dose-escalation... von Dowlati, Afshin, Harvey, R. Donald, Carvajal, Richard D., Hamid, Omid, Klempner, Samuel J., Kauh, John Sae Wook, Peterson, Daniel A., Yu, Danni, Chapman, Sonya C., Szpurka, Anna M., Carlsen, Michelle, Quinlan, Tonya, Wesolowski, Robert

Volltext

Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study von Autio, Karen A, Klebanoff, Christopher A, Schaer, David, Kauh, John Sae Wook, Slovin, Susan F, Adamow, Matthew, Blinder, Victoria S, Brahmachary, Manisha, Carlsen, Michelle, Comen, Elizabeth, Danila, Daniel C, Doman, Thompson N, Durack, Jeremy C, Fox, Josef J, Gluskin, Jill S, Hoffman, David M, Kang, Suhyun, Kang, Praneet, Landa, Jonathan, McAndrew, Philomena F, Modi, Shanu, Morris, Michael J, Novosiadly, Ruslan, Rathkopf, Dana E, Sanford, Rachel, Chapman, Sonya C, Tate, Courtney M, Yu, Danni, Wong, Phillip, McArthur, Heather L

Volltext

An Open-Label, Dose-Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma von Khalil, Danny N, Postow, Michael A, Ibrahim, Nageatte, Ludwig, Dale L, Cosaert, Jan, Kambhampati, Siva Rama Prasad, Tang, Shande, Grebennik, Dmitri, Kauh, John Sae Wook, Lenz, Heinz-Josef, Flaherty, Keith T, Hodi, F Stephen, Lawrence, Donald P, Wolchok, Jedd D

Volltext

Immunomodulatory Activity of a Colony-Stimulating Factor-1 Receptor Inhibitor in Patients With Advanced Refractory Breast or Prostate Cancer: A Phase 1 Study von Autio, Karen A., Klebanoff, Christopher A., Schaer, David, Kauh, John Sae Wook, Slovin, Susan F., Adamow, Matthew, Blinder, Victoria S., Brahmachary, Manisha, Carlsen, Michelle, Comen, Elizabeth, Danila, Daniel C., Doman, Thompson N., Durack, Jeremy C., Fox, Josef J., Gluskin, Jill S., Hoffman, David M., Kang, Suhyun, Kang, Praneet, Landa, Jonathan, McAndrew, Philomena F., Modi, Shanu, Morris, Michael J., Novosiadly, Ruslan, Rathkopf, Dana E., Sanford, Rachel, Chapman, Sonya C., Tate, Courtney M., Yu, Danni, Wong, Phillip, McArthur, Heather L.

Volltext

An Open-label, Dose-Escalation Phase 1 Study of anti-TYRP1 monoclonal antibody IMC-20D7S for patients with relapsed or refractory melanoma von Khalil, Danny N., Postow, Michael A., Ibrahim, Nageatte, Ludwig, Dale L., Cosaert, Jan, Kambhampati, Siva Rama Prasad, Tang, Shande, Grebennik, Dmitri, Kauh, John Sae Wook, Lenz, Heinz-Josef, Flaherty, Keith T., Hodi, F. Stephen, Lawrence, Donald P., Wolchok, Jedd D.

Volltext